Pediatric Moyamoya Biomarkers: Narrowing the Knowledge Gap

Laura L Lehman1, Matsanga Leyila Kaseka2, Jeffery Stout3

  • 1Department of Neurology, Boston Children's Hospital, Boston, MA; Harvard Medical School, Boston, MA.

Summary

Moyamoya disease, a progressive cerebrovascular disorder, requires better biomarkers for diagnosis and risk assessment in children. Identifying these biomarkers is crucial for determining optimal treatment, including revascularization surgery.